5Polymorphisms of cytokine and innate immunity genes and GVHD
Section snippets
Inflammatory cytokines and innate immune responses
Standard conditioning regimens which include total body irradiation (TBI) give rise to release of inflammatory cytokines including tumour necrosis factor α (TNFα) and interleukins 1 and 6 (IL-1 and IL-6).*1, *2 Release of these inflammatory cytokines into the patient's serum during conditioning has been correlated with an increased risk of more severe GVHD and poorer survival, whereas increased production of IL-10, a potent anti-inflammatory cytokine, seemed to be protective.*1, *3 In addition,
Phase 2 of GVHD: T-cell activation and chemokines
The second phase of GVHD involves activation of donor T cells via patient and donor APCs and release of Th1-type cytokines, especially IL-2 and interferon γ (IFNγ). Th2-type cytokines, such as IL-4, IL-5, IL-10 and IL-13, have also been described as modulating or exacerbating GVHD responses. Several SNP or microsatellite mutations also exist for these cytokine genes, and several have been studied with regard to HSCT outcome.
Effector-cell target organ damage
In the third phase of GVHD, cytotoxic effector cells as well as cytokines cause target-cell damage to the skin, gut and liver. In particular, cytotoxic T cells using the Fas and perforin pathways, together with NK cells and soluble TNF induced either by LPS-primed macrophages or donor T cells, cause damage, especially in the epithelial cells of the gut. IFNγ may sensitize both macrophages and epithelial cells and thus contribute to amplification of the cytotoxic response. Therefore, SNPs
Summary
In spite of the numerous reports, assessment of non-HLA genetics in relation to occurrence of acute and chronic GVHD has not yet been consistent between different cohorts of patients and donors. These limitations result from heterogeneity of clinical cofactors and treatment strategies, but should be overcome by large prospective analyses in homogeneous cohorts of transplants. Although the role of non-HLA markers in HSCT outcome is still not fully defined, there is no doubt that some of the
Acknowledgements
The authors wish to acknowledge support for their non-HLA genetics studies from the following European Commission grants: EUROBANK, contract no 2000 00 010; TRANSEUROPE, contract no QLK3-CT-2002-01936; TRANS-NET, contract no MRTN-CT-2004-512253; STEMDIAGNOSTICS, contract no LSHB-CT-2007-037703.
References (111)
- et al.
Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
Blood
(1994) - et al.
Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants
Blood
(1999) - et al.
Cytokine Gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants
Blood
(1998) - et al.
Highly informative typing of the human TNF locus using six adjacent polymorphic markers
Genomics
(1993) - et al.
Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation
Blood
(2004) - et al.
Cytokine gene polymorphism in patients with graft-versus-host disease
Transplantation Proceedings
(2001) - et al.
Host defence and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplant
Blood
(2002) - et al.
Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
Blood
(1994) - et al.
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation
The Journal of Biological Chemistry
(2000) - et al.
Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation
Blood
(2001)